<DOC>
	<DOCNO>NCT00003224</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide 946 may make body build immune response kill tumor cell . Combining vaccine protein tetanus vaccine , and/or either QS21 Montanide ISA-51 may effective treatment metastatic melanoma . PURPOSE : Randomized phase I trial study effectiveness vaccine make peptide 946 without tetanus peptide , QS21 , Montanide ISA-51 treat patient metastatic melanoma surgically remove melanoma likely recur .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety peptide 946 melanoma vaccine ( peptide 946 ) , peptide 946 combined tetanus peptide melanoma vaccine , peptide 946-tetanus peptide conjugate patient high risk melanoma . II . Determine immunogenicity peptide 946 melanoma vaccine ( peptide 946 ) , peptide 946 combined tetanus peptide melanoma vaccine , peptide 946-tetanus peptide conjugate patient high risk melanoma . OUTLINE : This randomize , open-label study . Patients randomize 1 6 treatment arm : Arm I : Patients receive peptide 946 melanoma vaccine ( peptide 946 ) emulsify QS21 subcutaneously ( SQ ) . Arm II : Patients receive peptide 946 emulsified Montanide ISA-51 ( ISA-51 ) SQ . Arm III : Patients receive peptide 946 combined tetanus peptide melanoma vaccine ( tetanus peptide ) emulsify QS21 SQ . Arm IV : Patients receive peptide 946 combined tetanus peptide emulsify ISA-51 SQ . Arm V : Patients receive peptide 946-tetanus peptide conjugate emulsify QS21 SQ . Arm VI : Patients receive peptide 946-tetanus peptide conjugate emulsify ISA-51 SQ . Initially , 4 patient randomized Arm I 4 patient randomize Arm II . If dose limit toxicity observe patient , additional patient randomize arm III-VI . Patients arm receive vaccine day 0 month 1 , 2 , 3 , 6 , 9 , 12 . Patients follow 6 12 month . PROJECTED ACCRUAL : A maximum 36 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm unresectable metastatic melanoma ( AJCC stage III IV ) OR resect melanoma high risk recurrence mortality ( stage IIB ) Age : 18 79 Performance status : ECOG 02 Life expectancy : Greater 12 month Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : AST ALT great 2.5 time upper limit normal ( ULN ) Bilirubin great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Exclusion criterion : patient currently receive cytotoxic chemotherapy receive therapy within precede 3 month know suspected allergy component treatment vaccine unresectable tumor llikely cause symptom therapy anticipate within 3 month . receive acute treatment seriouis infection within 14 day . Patients bulky disease , multiple brain metastasis , solitary brain metastasis treat successfully surgery gamma knife may eligible . Any following 3 month : agentes putative immunomodulating activity ( except NSAIDs ) allergy desensitize injection investigational agent interferon corticosteroid growth factor prior melanoma vaccination pregnancy possibility become pregnant study medical contraindication potential problem comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>